Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.47 |
| ▸ | WNT3A | P56704 | 4/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15979700 | 0.87 | DAO (0.61) | KMT2ADAOGSK3BNPC1RAB9A | |
| SCHEMBL15988687 | 0.87 | ALDH1A1 (0.48) | KMT2ADAOGSK3BNPC1RAB9A | |
| SCHEMBL10471221 | 0.86 | DAO (0.53) | KMT2ADAOCTNNB1WNT3ANPC1 | |
| SCHEMBL15979690 | 0.83 | KMT2A (0.54) | KMT2ADAOCTNNB1WNT3AGSK3B | |
| SCHEMBL15979663 | 0.83 | KMT2A (0.54) | KMT2ADAOCTNNB1WNT3AGSK3B | |
| SCHEMBL15988706 | 0.83 | MMP1 (0.54) | KMT2ADAOGSK3BALDH1A1MAPT | |
| SCHEMBL8762441 | 0.81 | SLC5A1 (0.50) | KMT2ADAONPC1RAB9APOLB | |
| SCHEMBL16552778 | 0.81 | KMT2A (0.83) | KMT2ACTNNB1WNT3AGSK3BNPC1 | |
| SCHEMBL15979688 | 0.81 | CTNNB1 (0.54) | KMT2ADAOCTNNB1WNT3ANPC1 | |
| SCHEMBL279619 | 0.80 | DAO (0.59) | KMT2ADAONPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20180193244-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-07-12 | — | — | US | disclosed |
| US-9951053-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170260176-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | MED-PATHWAYS II LIMITED (VG) | 2017-09-14 | — | — | US | disclosed |
| US-9533976-B2 | γ-diketones as WNT/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160206540-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2016-07-21 | — | — | US | disclosed |
| US-20160206540-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2016-07-21 | — | — | US | disclosed |
| US-20140243349-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2014-08-28 | — | — | US | disclosed |
| US-7902196-B2 | Synthesis of avrainvillamide, strephacidin B, and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193244-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | GLA, DGKG, DGKA | KMT2A 2193/4885DAO 239/4885CTNNB1 1789/4885 |
| US-20170260176-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | KMT2A 3457/4885DAO 3651/4885CTNNB1 6/4885 |
| US-20160206540-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | GLA, DGKG, DGKA | KMT2A 2193/4885DAO 239/4885CTNNB1 1789/4885 |
| US-20140243349-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | KMT2A 3457/4885DAO 3651/4885CTNNB1 6/4885 |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | KMT2A 3383/4885DAO 3757/4885CTNNB1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.